Nemes Rush Group LLC Sells 368 Shares of Amgen Inc. $AMGN

Nemes Rush Group LLC cut its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 73.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 135 shares of the medical research company’s stock after selling 368 shares during the period. Nemes Rush Group LLC’s holdings in Amgen were worth $38,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in AMGN. Private Management Group Inc. purchased a new stake in shares of Amgen in the second quarter worth approximately $385,000. Meridian Wealth Advisors LLC grew its holdings in Amgen by 0.6% during the second quarter. Meridian Wealth Advisors LLC now owns 8,214 shares of the medical research company’s stock worth $2,294,000 after buying an additional 49 shares in the last quarter. WealthBridge Capital Management LLC grew its holdings in Amgen by 23.6% during the second quarter. WealthBridge Capital Management LLC now owns 1,099 shares of the medical research company’s stock worth $307,000 after buying an additional 210 shares in the last quarter. New World Advisors LLC raised its position in Amgen by 64.9% in the 2nd quarter. New World Advisors LLC now owns 1,159 shares of the medical research company’s stock valued at $324,000 after buying an additional 456 shares during the last quarter. Finally, Cozad Asset Management Inc. lifted its stake in Amgen by 22.0% during the 2nd quarter. Cozad Asset Management Inc. now owns 2,133 shares of the medical research company’s stock valued at $596,000 after acquiring an additional 384 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently issued reports on AMGN shares. Bank of America upped their target price on shares of Amgen from $261.00 to $272.00 and gave the stock an “underperform” rating in a research note on Friday, September 26th. Scotiabank initiated coverage on shares of Amgen in a report on Thursday, November 13th. They set a “sector outperform” rating and a $385.00 price target on the stock. Raymond James Financial started coverage on shares of Amgen in a research note on Wednesday, September 3rd. They issued a “market perform” rating for the company. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Amgen from $280.00 to $285.00 and gave the stock a “hold” rating in a research report on Tuesday, November 11th. Finally, UBS Group reduced their target price on Amgen from $326.00 to $317.00 and set a “neutral” rating for the company in a report on Wednesday, August 6th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $320.86.

Insider Transactions at Amgen

In related news, SVP Nancy A. Grygiel sold 3,139 shares of Amgen stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $337.26, for a total value of $1,058,659.14. Following the completion of the sale, the senior vice president owned 7,225 shares of the company’s stock, valued at approximately $2,436,703.50. This trade represents a 30.29% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Murdo Gordon sold 6,879 shares of the business’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total value of $2,317,053.57. Following the completion of the sale, the executive vice president owned 41,923 shares in the company, valued at $14,120,924.09. This represents a 14.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 10,908 shares of company stock worth $3,674,966. 0.76% of the stock is owned by company insiders.

Amgen Stock Down 1.0%

AMGN opened at $334.30 on Tuesday. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $345.84. The company’s 50-day moving average price is $302.19 and its two-hundred day moving average price is $293.02. The stock has a market cap of $180.01 billion, a price-to-earnings ratio of 27.33, a PEG ratio of 2.61 and a beta of 0.45. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 7.24.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 EPS for the quarter, topping analysts’ consensus estimates of $5.01 by $0.63. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The company had revenue of $9.56 billion for the quarter, compared to analysts’ expectations of $8.98 billion. During the same quarter in the previous year, the firm posted $5.58 EPS. Amgen’s revenue was up 12.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. As a group, equities analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, December 12th. Stockholders of record on Friday, November 21st will be given a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend is Friday, November 21st. Amgen’s dividend payout ratio is currently 73.57%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.